New Sight in Cancer Genetics—2nd Edition

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Cancer Biology".

Deadline for manuscript submissions: 31 May 2026 | Viewed by 281

Special Issue Editors


E-Mail Website
Guest Editor
1. Cytogenetics and Genomics Laboratory, Institute of Cellular and Molecular Biology, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
2. Institute for Clinical and Biomedical Research (iCBR), Center of Investigation on Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine (FMUC), University of Coimbra, 3004-531 Coimbra, Portugal
Interests: genomic; omics in cancer; head and neck cancer; methylation and genetic mechanisms; oncobiology; copy number alterations; prognosis biomarkers
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Cytogenetics and Genomics Laboratory, Institute of Cellular and Molecular Biology, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
2. Institute for Clinical and Biomedical Research (iCBR), Center of Investigation on Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine (FMUC), University of Coimbra, 3004-531 Coimbra, Portugal
Interests: cytogenetics; human genetics; cancer genetics; oncobiology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Medicine, Cancer Research Center (IBMCC-CSIC/USAL), CIBERONC and Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca (USAL), Salamanca, Spain
Interests: leukemia; lymphoma; early cancer diagnosis; immunophenotyping; genetics; diagnosis; prognosis; minimal residual disease; immune monitoring; CART; EuroFlow
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In general, it has remained challenging to treat cancer despite the innovative and revolutionary research taking place worldwide. The remarkable advances over the last decade in multi-omics technologies, especially next-generation sequencing (NGS) and genome analysis, have led to significant improvements in our knowledge of the molecular mechanisms of cancer. Together with bioinformatic tools and Artificial Intelligence, it is possible to use computer programming to improve cancer diagnosis, drug development, and precision medicine.

This Special Issue aims to present robust molecular signatures and biomarkers of unmet clinical problems in cancer fields, mostly focusing on predicting treatment response, making early diagnoses, and assessing disease prognosis through the use of different omics approaches, such as genomic, epigenomic, transcriptomic, proteomic, and metabolomic methods. We welcome original research articles and reviews to this Special Issue. Research areas may include (but are not limited to) the following topic: new developments in cancer research in order to identify biomarkers and molecular signatures with high possibility of clinical application and therapeutic development.

We look forward to receiving your contributions.

Dr. Ilda Patrícia Ribeiro
Prof. Dr. Isabel Marques Carreira
Prof. Dr. Alberto Orfao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genomic and epigenetic characterization
  • diagnosis and prognosis biomarkers
  • omics profiles
  • genetic and genomic signature
  • molecular heterogeneity
  • molecular targeted therapy
  • oncogenic signaling pathways
  • copy number alterations and mutational landscape
  • chromosome abnormalities

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

55 pages, 2394 KiB  
Review
Salivaomic Biomarkers—An Innovative Approach to the Diagnosis, Treatment, and Prognosis of Oral Cancer
by Katarzyna Starska-Kowarska
Biology 2025, 14(7), 852; https://doi.org/10.3390/biology14070852 (registering DOI) - 13 Jul 2025
Viewed by 196
Abstract
(1) Background: Oral cancer (OC) is one of the most frequently diagnosed human cancers and remains a challenge for biologists and clinicians. More than 90% of OC cases are squamous cell carcinomas (OSCCs). Despite the use of modern diagnostic and prognostic methods, the [...] Read more.
(1) Background: Oral cancer (OC) is one of the most frequently diagnosed human cancers and remains a challenge for biologists and clinicians. More than 90% of OC cases are squamous cell carcinomas (OSCCs). Despite the use of modern diagnostic and prognostic methods, the 5-year survival rate remains unsatisfactory due to the late diagnosis of the neoplastic process and its resistance to treatment. This comprehensive review aims to present the latest literature data on the use and effectiveness of saliva as a non-invasive biomarker in patients with oral cancer. (2) Methods: The article reviews the current literature on the use of salivary omics biomarkers as an effective method in diagnosing and modifying treatment in patients with OSCC; the research corpus was acquired from the PubMed/Google/Scopus/Cochrane Library/Web of Science databases in accordance with the Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA 2020) guidelines. (3) Results: The identification of salivary omics biomarkers involved in carcinogenesis and neoplastic transformation may be a potential alternative to traditional invasive diagnostic methods. Saliva, being both an abundant reservoir of organic and inorganic components derived from epithelial cells as well as a cell-free environment, is becoming an interesting diagnostic material for studies in the field of proteomics, genomics, metagenomics, and metabolomics. (4) Conclusions: Saliva-based analysis is a modern and promising method for the early diagnosis and improvement of treatment outcomes in patients with OSCC and oral potentially malignant disorders (OPMDs), with high diagnostic, therapeutic, and prognostic potential. Full article
(This article belongs to the Special Issue New Sight in Cancer Genetics—2nd Edition)
Show Figures

Figure 1

Back to TopTop